Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study
2017 ◽
Vol 167
(2)
◽
pp. 479-483
◽
2017 ◽
Vol 99
(2)
◽
pp. S170-S171